JP7297770B2 - 結腸がんの検出および治療の方法 - Google Patents

結腸がんの検出および治療の方法 Download PDF

Info

Publication number
JP7297770B2
JP7297770B2 JP2020540396A JP2020540396A JP7297770B2 JP 7297770 B2 JP7297770 B2 JP 7297770B2 JP 2020540396 A JP2020540396 A JP 2020540396A JP 2020540396 A JP2020540396 A JP 2020540396A JP 7297770 B2 JP7297770 B2 JP 7297770B2
Authority
JP
Japan
Prior art keywords
score
subject
biomarkers
colon cancer
pop7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020540396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511057A (ja
JPWO2019144099A5 (https=
JP2021511057A5 (https=
Inventor
マーク モドリン アービン
キッド マーク
ドロズドフ イグナット
Original Assignee
リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー filed Critical リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー
Publication of JP2021511057A publication Critical patent/JP2021511057A/ja
Publication of JPWO2019144099A5 publication Critical patent/JPWO2019144099A5/ja
Publication of JP2021511057A5 publication Critical patent/JP2021511057A5/ja
Application granted granted Critical
Publication of JP7297770B2 publication Critical patent/JP7297770B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
JP2020540396A 2018-01-22 2019-01-22 結腸がんの検出および治療の方法 Active JP7297770B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620015P 2018-01-22 2018-01-22
US62/620,015 2018-01-22
PCT/US2019/014490 WO2019144099A1 (en) 2018-01-22 2019-01-22 Methods for colon cancer detection and treatment monitoring

Publications (4)

Publication Number Publication Date
JP2021511057A JP2021511057A (ja) 2021-05-06
JPWO2019144099A5 JPWO2019144099A5 (https=) 2022-01-31
JP2021511057A5 JP2021511057A5 (https=) 2022-01-31
JP7297770B2 true JP7297770B2 (ja) 2023-06-26

Family

ID=65279827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540396A Active JP7297770B2 (ja) 2018-01-22 2019-01-22 結腸がんの検出および治療の方法

Country Status (15)

Country Link
US (3) US11414707B2 (https=)
EP (1) EP3743534B1 (https=)
JP (1) JP7297770B2 (https=)
KR (1) KR20200113237A (https=)
CN (1) CN112004945B (https=)
AU (1) AU2019209436B2 (https=)
BR (1) BR112020014737A2 (https=)
CA (1) CA3088754A1 (https=)
DK (1) DK3743534T3 (https=)
ES (1) ES2917629T3 (https=)
IL (1) IL276089B2 (https=)
MX (1) MX2020007771A (https=)
PL (1) PL3743534T3 (https=)
SG (1) SG11202006974WA (https=)
WO (1) WO2019144099A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3743534T3 (pl) 2018-01-22 2022-09-05 Liquid Biopsy Research LLC Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
US11809379B2 (en) * 2019-11-19 2023-11-07 International Business Machines Corporation Storage tiering for deduplicated storage environments
CN111157745A (zh) * 2020-01-17 2020-05-15 上海交通大学 人snrpa蛋白在肺癌复发或转移监测中的用途
CN115475247B (zh) * 2021-06-16 2024-02-20 厦门大学 β2-微球蛋白或其抑制剂的制药用途
KR102823777B1 (ko) * 2021-10-15 2025-06-23 한국과학기술원 인공지능을 이용하여 유전체 염기서열로 질환 진단 및 예측 방법, 그 시스템
CN113921079B (zh) * 2021-12-06 2022-03-18 四川省肿瘤医院 基于免疫相关基因的msi预测模型构建方法
CN121137146B (zh) * 2025-07-28 2026-04-07 首钢医院有限公司 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503222A (ja) 2011-01-18 2014-02-13 エバリスト ジェノミックス， インコーポレイテッド 結腸直腸がん再発に関する予後のサイン
JP2016104014A (ja) 2009-05-01 2016-06-09 ジェノミック ヘルス， インコーポレイテッド 結腸直腸癌の再発および化学療法に対する応答の可能性における遺伝子発現プロファイルアルゴリズムおよび試験

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2169077A1 (en) * 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
EP2169078A1 (en) 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
KR101051435B1 (ko) * 2008-10-22 2011-07-22 한국생명공학연구원 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법
KR101073875B1 (ko) 2008-11-28 2011-10-14 한국생명공학연구원 대장암 진단 마커 및 이를 이용한 대장암 진단방법
EP2309002A1 (en) * 2009-09-29 2011-04-13 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of colorectal cancer aggressiveness
ES2525382T3 (es) * 2010-03-31 2014-12-23 Sividon Diagnostics Gmbh Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
EP2426216A1 (en) * 2010-09-01 2012-03-07 Institut Gustave Roussy (IGR) Prognostic and/or predictive biomarkers and biological applications thereof
JP2014509189A (ja) 2011-01-25 2014-04-17 アルマック ダイアグノスティックス リミテッド 結腸ガン遺伝子発現シグネチャーおよび使用方法
US20150226744A1 (en) * 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
PL3743534T3 (pl) 2018-01-22 2022-09-05 Liquid Biopsy Research LLC Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104014A (ja) 2009-05-01 2016-06-09 ジェノミック ヘルス， インコーポレイテッド 結腸直腸癌の再発および化学療法に対する応答の可能性における遺伝子発現プロファイルアルゴリズムおよび試験
JP2014503222A (ja) 2011-01-18 2014-02-13 エバリスト ジェノミックス， インコーポレイテッド 結腸直腸がん再発に関する予後のサイン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Alessio Tempestini et al.，Oncology Research，2006年，Vol.16，pp.143-156
Priyanka Kanth et al.，Cancer Prev Res (Phila)，2016年，Vol.9, No.6，pp.456-465

Also Published As

Publication number Publication date
CA3088754A1 (en) 2019-07-25
JP2021511057A (ja) 2021-05-06
EP3743534A1 (en) 2020-12-02
SG11202006974WA (en) 2020-08-28
IL276089A (en) 2020-08-31
IL276089B2 (en) 2024-07-01
AU2019209436B2 (en) 2025-06-05
AU2019209436A1 (en) 2020-08-06
DK3743534T3 (da) 2022-06-20
CN112004945A (zh) 2020-11-27
EP3743534B1 (en) 2022-03-23
KR20200113237A (ko) 2020-10-06
US20230220482A1 (en) 2023-07-13
PL3743534T3 (pl) 2022-09-05
WO2019144099A1 (en) 2019-07-25
MX2020007771A (es) 2020-09-03
IL276089B1 (en) 2024-03-01
US20250243553A1 (en) 2025-07-31
BR112020014737A2 (pt) 2020-12-08
US20190226030A1 (en) 2019-07-25
US11414707B2 (en) 2022-08-16
ES2917629T3 (es) 2022-07-11
CN112004945B (zh) 2025-02-14
US12305240B2 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
JP7297770B2 (ja) 結腸がんの検出および治療の方法
ES3023842T3 (en) Methods for prostate cancer detection and treatment
JP7724265B2 (ja) 遺伝子発現アッセイを使った予測ペプチド受容体放射性核種療法
HK40042084A (en) Methods for colon cancer detection and treatment monitoring
HK40042084B (en) Methods for colon cancer detection and treatment monitoring
HK40043345A (en) Methods for prostate cancer detection and treatment
HK40043345B (en) Methods for prostate cancer detection and treatment
HK40035975A (en) Predicting peptide receptor radiotherapy using a gene expression assay
HK40035975B (en) Predicting peptide receptor radiotherapy using a gene expression assay

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230614

R150 Certificate of patent or registration of utility model

Ref document number: 7297770

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250